Arrowhead Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
- Conditions
- C3 GlomerulopathyIgA Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT05083364
- Locations
- πΉπ
Research Site 3, Chiang Mai, Thailand
π³πΏResearch Site, Auckland, New Zealand
πΉπResearch Site 2, Bangkok, Thailand
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04998201
- Locations
- πΊπΈ
Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States
πΊπΈPreventive Cardiology Inc., Boca Raton, Florida, United States
πΊπΈA & R Research Group, Pembroke Pines, Florida, United States
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04832971
- Locations
- πΊπΈ
Baylor College of Medicine, Houston, Texas, United States
πΊπΈAGA Clinical Trials, Hialeah, Florida, United States
πΊπΈMedication Management LLC, Greensboro, North Carolina, United States
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04720534
- Locations
- πΊπΈ
Pioneer Research Solutions, Inc., Houston, Texas, United States
πΊπΈClinical Research of South Nevada, Las Vegas, Nevada, United States
πΊπΈAppleMed Research Group, Miami, Florida, United States
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT04375514
- Locations
- π³πΏ
Research Site, Dunedin, New Zealand
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: ARO-HSD InjectionDrug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT04202354
- Locations
- π³πΏ
Auckland Clinical Studies, Grafton, Auckland, New Zealand
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT04169711
- Locations
- πΊπΈ
Research Site, Houston, Texas, United States
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT03946449
- Locations
- π¬π§
Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom
π¬π§Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom
π©πͺUniversitatsklinikum Aachen, Anstalt des offentlich, Aachen, Germany
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Drug: Fazisiran InjectionOther: Placebo
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03945292
- Locations
- πΊπΈ
UCLA David Geffen School of Medicine, Center for Health Sciences, Los Angeles, California, United States
πΊπΈUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
πΊπΈUniversity of California San Diego Altman Clinical and Translational Research Institute, La Jolla, California, United States
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- HypertriglyceridemiaFamilial Chylomicronemia
- Interventions
- Drug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03783377
- Locations
- π¦πΊ
Linear Clinical Research, Perth, Western Australia, Australia
π¦πΊRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia
π¦πΊRoyal Adelaide Hospital, Adelaide, South Australia, Australia